Spotting
 Timeline
 Travel Tip
 Trip
 Race
 Social
 Greeting
 Poll
 Img
 PNR
 Pic
 Blog
 News
 Conf TL
 RF Club
 Convention
 Monitor
 Topic
 Followed
 Rating
 Correct
 Wrong
 Stamp
 HJ
 Vote
 Pred
 @
 FM Alert
 FM Approval
 Pvt
News Super Search
 ↓ 
×
Member:
Posting Date From:
Posting Date To:
Category:
Zone:
Language:
IR Press Release:

Search
  Go  

Vivek Express - জেগে ওঠো, সচেতন হও এবং লক্ষ্যে না পৌঁছানো পর্যন্ত থেমো না - Dip

Full Site Search
  Full Site Search  
 
Mon Oct 26 07:03:37 IST
Home
Trains
ΣChains
Atlas
PNR
Forum
Topics
Gallery
News
FAQ
Trips/Spottings
Login
Advanced Search
<<prev entry    next entry>>
News Entry# 419283
Sep 23 (11:21) Coronavirus vaccine update: Bharat Biotech plans to begin phase-3 testing of Covaxin in October (www.moneycontrol.com)
*business
0 Followers
365 views

News Entry# 419283  Blog Entry# 4723110   
  Past Edits
This is a new feature showing past edits to this News Post.
Last Updated : Sep 23, 2020 11:10 AM IST |
Bharat Biotech plans to test the Covaxin vaccine on about 25,000-30,000 people in phase -3
Vaccine maker Bharat Biotech plans to start the phase-3 clinical trial of its COVID-19 vaccine Covaxin in October to test safety and efficacy.
The company plans to test the vaccine on about 25,000 - 30,000 people in phase -3.
...
more...

Currently, Covaxin, which is based on the inactivated whole virion of SARS-CoV2 is in the phase-2 trial. Bharat Biotech has completed the phase-1 and submitted the data to Drug Controller General of India (DCGI).
Meanwhile, Bharat Biotech said it is producing vaccines at risk at two of its Biosafety Safety Level (BSL)-3 facilities in Hyderabad.
"The current capacity is 100-200 million doses at these two facilities," said Sai Prasad, President, Quality Operations at Bharat Biotech.
Prasad said the company is exploring possibilities of manufacturing Covaxin at partner sites through technology transfer agreements.
The company is also in talks with other partners and looking at possibilities of manufacturing the vaccine in 4-5 countries. It is looking at having at least 1 billion doses per annum manufacturing capacity of Covaxin.
Scroll to Top
Scroll to Bottom
Go to Mobile site
Important Note: This website NEVER solicits for Money or Donations. Please beware of anyone requesting/demanding money on behalf of IRI. Thanks.
Disclaimer: This website has NO affiliation with the Government-run site of Indian Railways. This site does NOT claim 100% accuracy of fast-changing Rail Information. YOU are responsible for independently confirming the validity of information through other sources.
India Rail Info Privacy Policy